User: Guest  Login
Title:

Interleukin-6-controlled, mesenchymal stem cell-based sodium/iodide symporter gene therapy improves survival of glioblastoma-bearing mice.

Document type:
Journal Article
Author(s):
Kitzberger, Carolin; Shehzad, Khuram; Morath, Volker; Spellerberg, Rebekka; Ranke, Julius; Steiger, Katja; Kälin, Roland E; Multhoff, Gabriele; Eiber, Matthias; Schilling, Franz; Glass, Rainer; Weber, Wolfgang A; Wagner, Ernst; Nelson, Peter J; Spitzweg, Christine
Abstract:
New treatment strategies are urgently needed for glioblastoma (GBM)-a tumor resistant to standard-of-care treatment with a high risk of recurrence and extremely poor prognosis. Based on their intrinsic tumor tropism, adoptively applied mesenchymal stem cells (MSCs) can be harnessed to deliver the theranostic sodium/iodide symporter (NIS) deep into the tumor microenvironment. Interleukin-6 (IL-6) is a multifunctional, highly expressed cytokine in the GBM microenvironment including recruited MSCs....     »
Journal title abbreviation:
Mol Ther Oncolytics
Year:
2023
Journal volume:
30
Pages contribution:
238-253
Fulltext / DOI:
doi:10.1016/j.omto.2023.08.004
Pubmed ID:
http://view.ncbi.nlm.nih.gov/pubmed/37701849
TUM Institution:
594; 602; Institut für Allgemeine Pathologie und Pathologische Anatomie (Dr. Mogler komm.); Klinik und Poliklinik für Nuklearmedizin (Prof. Weber); Klinik und Poliklinik für RadioOnkologie und Strahlentherapie (Prof. Combs)
 BibTeX